查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1696289

全球人工胰臟系統市場 - 2025 至 2033 年

Global Artificial Pancreas System Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球人工胰臟系統市場規模達到 4.5697 億美元，預計到 2033 年將達到 63.047 億美元，2025-2033 年預測期內的複合年成長率為 30.0%。

人工胰臟系統是一種自動控制第一型糖尿病患者血糖的醫療設備。它包括連續血糖監測儀、胰島素幫浦和先進的控制演算法。該系統模仿健康胰臟的功能，確保最佳血糖水平並降低高血糖和低血糖的風險。它改善了糖尿病管理和患者的便利性，並最大限度地減少了手動注射胰島素的需要。

市場動態：

促進因素與約束因素

糖尿病盛行率上升

全球糖尿病的流行，尤其是第1型糖尿病，正在推動人工胰臟系統市場的發展。許多醣尿病患者需要持續的血糖管理，因此對自動化解決方案的需求很大。感測器技術的進步改善了胰島素的輸送，人工智慧驅動的演算法透過提供高效、個人化的糖尿病管理解決方案促進了市場成長。

例如，根據國際糖尿病基金會的預測，到 2045 年，糖尿病盛行率將增加 46%，超過 90% 的患者患有第 2 型糖尿病。導致這種成長的因素包括城市化、人口老化、體力活動減少以及超重和肥胖的增加，而社會經濟、人口、環境和遺傳因素則加劇了這些因素的出現。

因此，糖尿病盛行率的增加將推動對人工胰臟裝置系統的需求。這種需求，加上城市化和生活方式相關的風險因素，需要先進的血糖管理解決方案，從而導致自動胰島素輸送市場的擴大。

人工胰臟系統成本高昂

儘管人工胰臟系統在糖尿病管理方面具有潛在益處，但在市場擴張方面仍面臨重大障礙，尤其是在中低收入國家。先進組件的高成本、有限的報銷政策以及高昂的維護成本進一步限制了其採用，限制了其廣泛使用。例如，帶有 Control-IQ 的 Tandem t:slim X2 泵售價約為 4,000 美元，保險通常可承擔 80% 的費用。 Dexcom G6 CGM 耗材（例如發射器和感測器）的額外成本可能相當高。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與關鍵要點

第3章：市場亮點與策略要點

  • 主要趨勢和未來預測
  • 按設備類型分類的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 糖尿病盛行率上升
      • 穿戴式和人工智慧醫療設備的普及率不斷提高
    • 限制
      • 人工胰臟系統成本高昂
      • 嚴格的監管要求和核准延遲
    • 機會
      • 人工智慧與機器學習的融合，實現個人化糖尿病管理
    • 影響分析

第5章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：按裝置類型

  • 閾值暫停設備系統
  • 僅胰島素系統
  • 雙重荷爾蒙系統

第 7 章：按最終用戶

  • 醫院
  • 診所
  • 家庭護理設置
  • 門診手術中心

第 8 章：區域市場分析與成長機會

第9章：簡介

  • 北美洲
    • 各區域關鍵動態
      • 美國
      • 加拿大
  • 歐洲
    • 各區域關鍵動態
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 義大利
      • 歐洲其他地區
  • 拉丁美洲
    • 各區域關鍵動態
      • 墨西哥
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地區
  • 亞太
    • 各區域關鍵動態
      • 中國
      • 印度
      • 日本
      • 韓國
      • 亞太其他地區
  • 中東和非洲
    • 各區域關鍵動態

第 10 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
    • 市佔率分析與定位矩陣
    • 策略夥伴關係、併購
    • 產品組合和創新的關鍵發展
    • 公司基準化分析

第 11 章：公司簡介

  • Medtronic Plc
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
      • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
      • SWOT 分析
  • Tandem Diabetes Care, Inc
  • Beta Bionics
  • Insulet Corporation
  • Diabeloop
  • Inreda Diabetic BV
  • Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

第 12 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 13 章：附錄

簡介目錄
Product Code: MD9415

The global artificial pancreas system market reached US$ 456.97 million in 2024 and is expected to reach US$ 6304.70 million by 2033, growing at a CAGR of 30.0% during the forecast period 2025-2033.

Artificial pancreas system is a medical device that automates blood glucose control in type 1 diabetes patients. It includes a continuous glucose monitor, insulin pump, and advanced control algorithm. This system mimics the function of a healthy pancreas, ensuring optimal blood sugar levels and reducing the risk of hyperglycemia and hypoglycemia. It improves diabetes management and patient convenience and minimizes the need for manual insulin administration.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The global diabetes prevalence, particularly type 1, is driving the artificial pancreas system market. Many diabetes patients need continuous blood glucose management, leading to a demand for automated solutions. Advancements in sensor technology improved insulin delivery, and AI-driven algorithms are contributing to market growth by offering efficient, personalized diabetes management solutions.

For instance, according to International Diabetes Foundation by 2045, IDF projections indicate a 46% increase in diabetes prevalence, with over 90% of individuals having type 2 diabetes. Factors contributing to this increase include urbanization, an aging population, decreased physical activity, and an increase in overweight and obesity, which are exacerbated by socio-economic, demographic, environmental, and genetic factors.

Hence, an increase in the prevalence of diabetes will drive demand for artificial pancreas device systems. This demand, coupled with urbanization and lifestyle-related risk factors, necessitates advanced glucose management solutions, leading to market expansion for automated insulin delivery.

High Cost of Artificial Pancreas Systems

Artificial pancreas systems, despite their potential benefits in diabetes management, face significant barriers to market expansion, particularly in low- and middle-income countries. The high cost of advanced components, limited reimbursement policies, and high maintenance costs further restrict adoption, limiting their widespread use. For instance, The Tandem t:slim X2 pump with Control-IQ costs around $4,000, with insurance typically covering 80% of the cost. Additional costs for Dexcom G6 CGM supplies, such as a transmitter and sensors, can be significant.

Segment Analysis

The global artificial pancreas system market is segmented based on device type, end-user, and region.

Device Type:

The threshold suspend device systems from the device type segment is expected to dominate the artificial pancreas system market with the highest market share

The threshold suspend and predictive suspend systems are tools that temporarily suspend insulin delivery when blood glucose levels drop below a pre-set level. These systems calculate blood glucose levels and stop delivering insulin before they reach too low. They do not automatically increase insulin doses. Storing insulin at the right moment can help prevent low blood sugar, or hypoglycemia, in individuals with type 1 diabetes. These systems may also assist those who develop hypoglycemia overnight, especially children.

The rise in diabetes, particularly type 1, is driving the adoption of Threshold Suspend Device Systems. This is driven by increased awareness of hypoglycemia risks and the need for automated insulin delivery systems. Technological advancements, regulatory approvals, healthcare expenditure, and expanded reimbursement policies in developed regions contribute to the adoption of these life-saving devices.

Geographical Analysis

North America is expected to hold a significant position in the artificial pancreas system market with the highest market share

North America dominates the threshold suspend device systems market due to advanced healthcare infrastructure, high diabetes management technologies, and key market players. The region's large type 1 diabetes population drives demand for automated insulin delivery solutions. Benefits from reimbursement policies, continuous glucose monitoring awareness, and technological advancements in insulin pumps drive market growth. Government initiatives, increased healthcare expenditure, and personalized medicine focus contribute to the growing adoption of Threshold Suspend Device Systems in North America.

Moreover, FDA approvals are also a significant factor that helps the region to grow during the forecast period. For instance, in May 2024, The U.S. Food and Drug Administration (FDA) approved an artificial pancreas developed by University of Cambridge researchers for use by individuals with type 1 diabetes, including during pregnancy, marking the first time the FDA has authorized the use of this life-changing app during pregnancy.

Moreover, in May 2023, the FDA approved the iLet Insulin-Only Bionic Pancreas System for individuals aged 6 and above with type 1 diabetes, an artificial pancreas system that autonomously determines and delivers insulin doses.

Competitive Landscape

The major global players in the artificial pancreas system market include Medtronic Plc, Tandem Diabetes Care, Inc., Beta Bionics, Insulet Corporation, Diabeloop, Inreda Diabetic B.V., and Nikkiso Co., Ltd among others.

Key Developments

  • In April 2024, the NHS launched a world-first initiative for tens of thousands of children and adults with type 1 diabetes in England, which will use an 'artificial pancreas' to monitor blood glucose levels and automatically adjust insulin dosage.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial pancreas system market report delivers a detailed analysis with 45key tables, more than 40 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

3. Market Highlights and Strategic Takeaways

  • 3.1. Key Trends and Future Projections
  • 3.2. Snippet by Device Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetes
      • 4.1.1.2. Growing Adoption of Wearable and AI-driven Healthcare Devices
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Artificial Pancreas Systems
      • 4.1.2.2. Stringent Regulatory Requirements and Approval Delays
    • 4.1.3. Opportunity
      • 4.1.3.1. Integration of AI and Machine Learning for Personalized Diabetes Management
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Device Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 6.1.2. Market Attractiveness Index, By Device Type
  • 6.2. Threshold Suspend Device Systems*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Insulin-only Systems
  • 6.4. Dual Hormone Systems

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Clinics
  • 7.4. Homecare Settings
  • 7.5. Ambulatory Surgical Centers

8. Regional Market Analysis and Growth Opportunities

9. Introduction

  • 9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.1. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Spain
      • 9.3.5.5. Italy
      • 9.3.5.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Mexico
      • 9.4.5.2. Brazil
      • 9.4.5.3. Argentina
      • 9.4.5.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. South Korea
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
    • 10.1.1. Market Share Analysis and Positioning Matrix
    • 10.1.2. Strategic Partnerships, Mergers & Acquisitions
    • 10.1.3. Key Developments in Product Portfolios and Innovations
    • 10.1.4. Company Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.1.1. Geographical Revenue Shares
      • 11.1.3.1.1.1. Revenue Forecasts
      • 11.1.3.1.2. Key Developments
      • 11.1.3.1.2.1. Mergers & Acquisitions
      • 11.1.3.1.2.2. Key Product Development Activities
      • 11.1.3.1.2.3. Regulatory Approvals, etc.
      • 11.1.3.1.3. SWOT Analysis
  • 11.2. Tandem Diabetes Care, Inc
  • 11.3. Beta Bionics
  • 11.4. Insulet Corporation
  • 11.5. Diabeloop
  • 11.6. Inreda Diabetic B.V
  • 11.7. Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us